CBD and Neuropathy


An oromucosal spray named Sativex was approved back in 2005 by the Canadian governmentfor use in treating neuropathy.

While Sativex itself is a brand name and must be obtained with a prescription, the important thing to note is that it is essentially just a combination of THC and CBD, cannabidiol, not much different than just using a full spectrum hemp extractin combination with THC. Let’s be real: it literally is just a full spectrum cannabis extract, extracted with ethanol, packaged up and branded by GW Pharmaceuticals. This is something you could buy yourself.

Sativex (THC + CBD) was found in multiple clinical trials to be extremely effective in controlling neuropathy pain in MS patients, as well as arthritis. It was later approved by the United States FDA in 2006 for trials to control cancer related neuropathy.

Historically, and quite ironically, Western understanding of the biological underpinnings of the pain system in the body was originally glimpsed through the lens of studying the plants Cannabis, opium poppies, Willow bark, and chile peppers.

Out of the study of these plants – and the naturally effective medicine inherent in them – pharmaceutical companies formulated synthetic, highly addictive, drugs such as morphine, codeine, oxycontin.

Due to lack of commercial feasibility and patentability, pharmaceutical companies, before the early 2000s, have not made any endocannabinoid drug-derivatives.

 Cannabinoids, however, are very well known for their analgesic effect in controlling pain in humans. Ask any anesthesiologist and they will agree, activation of the CB1 receptor (cannabinoid receptor 1) will lead to almost immediate alleviation of pain and inflammation. This pain reduction can be seen in fibromyalgia patients when treated with cannabis

and even in cases of intestinal pain with IBS.

Cannabinoids like CBD, cannabidiol have been shown to alleviate this pain by also activating glycine receptors.

This study found some really convincing evidence for this neuropathic pain control in rats.

According to the researchers,

“The non-psychoactive compound, cannabidiol, or CBD, is the only component present at a high level in the extract able to bind to this receptor: thus cannabidiol was the compound responsiblefor the antinociceptive behaviour observed.